Abstracts tagged "ANCA"

Abstract Number: 858 • 2015 ACR/ARHP Annual Meeting
Stimulated Renal Glomerular Endothelial Cells Were Damaged By Fiber-like NETs Released By Neutrophils in ANCA-Associated Vasculitis
Yoshinori Komagata¹, Kanako Murakami¹, Chimako Kida¹, Kazuhito Fukuoka¹, Miho Karube², Shinya Kaname¹ and Yoshihiro Arimura¹, ¹First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ²Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: NETosis, a unique form of cell death of neutrophils, is characterized by the active release of chromatin fibers called NETs, that trap and kill…
Abstract Number: 2415 • 2015 ACR/ARHP Annual Meeting
Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States
Karen James¹, Rui Xiao², Peter A. Merkel³ and Pamela F. Weiss¹, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: ANCA-associated vasculitis (AAV) is a group of rare systemic vasculitidies with significant morbidity and mortality. Plasma exchange (PLEX) has been shown to decrease risk…
Abstract Number: 859 • 2015 ACR/ARHP Annual Meeting
Predictors of Renal Histopathology in Antineutrophil Cytoplasmic Antibody Associated Glomerulonephritis
Sophia Lionaki¹, Clio Mavragani², George Liapis³, George Somarakis⁴, John Boletis¹, Alexandros A. Drosos⁵, Athanasios G. Tzioufas⁶ and Haralampos M. Moutsopoulos⁶, ¹Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, ²Physiology, Department of Physiology, School of Medicine, National Kapodistrian University of Athens, Athens, Greece, ³Pathology, Laiko Hospital, Department of Pathology, Athens, Greece, ⁴Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ⁵Dept of Internal Medicine, University of Ioannina, Rheumatology Clinic, Ioannina, Greece, ⁶Department of Pathophysiology, Medical School of Athens, Department of Pathophysiology, Athens, Greece
Background/Purpose: Prompt, aggressive therapy is vital for anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In this regard, we aimed to identify predictors of distinct renal histopathological…
Abstract Number: 861 • 2015 ACR/ARHP Annual Meeting
ANCA-Associated Pauci-Immune Glomerulonephritis: ¿Always Pauci-Immune?
Valeria Scaglioni¹, Marina Scolnik¹, Luis J. Catoggio¹, Carlos Federico Varela², Gustavo Greloni², Silvia Christiansen³ and Enrique R. Soriano⁴, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Internal Medicine, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN) is considered a “pauci-immune” disease, characterized by absent or mild glomerular tuft staining for immunoglobulin and/or complement. However,…
Abstract Number: 1777 • 2014 ACR/ARHP Annual Meeting
Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA-Associated Vasculitis
Boun Kim Tan¹, Yoann Crabol¹, Jason Tasse^2,3, Frederic Laurent^2,3, Xavier Puechal^4,5, Christine Vinter⁶ and Loïc Guillevin^1,5, ¹Internal Medicine, Hôpital Cochin, University Paris V Descartes, Paris, France, ²Laboratoire de Bactériologie de l'hôpital de la Croix-Rousse, National Reference Centre for Staphylococci, Lyon, France, ³INSERM U1111, CNRS UMR5308, International Centre for Research in Infectious Diseases, Lyon, France, ⁴Internal Medicine, Hôpital Cochin, Paris, France, ⁵French Vasculitis Study Group (FVSG), Paris, France, ⁶Internal Medecine, Hôpital Cochin, Paris, France
Background/Purpose Staphylococcus aureus (SA) nasal carriage has been reported to be more frequent and associated with persistent ANCA-positivity and relapse in patients with granulomatosis with…
Abstract Number: 1776 • 2014 ACR/ARHP Annual Meeting
Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy
Benjamin Terrier¹, Christian Pagnoux², Guillaume Geri³, Alexandre Karras⁴, Chahéra Khouatra⁵, Olivier Aumaitre⁶, Pascal Cohen⁷, Francois Maurier⁸, Olivier Decaux⁹, Hélène Desmurs-Clavel¹⁰, Pierre Gobert¹¹, Thomas Quemeneur¹², Claire Blanchard-Delaunay¹³, Pascal Godmer¹⁴, Xavier Puéchal⁷, Luc Mouthon⁷ and Loïc Guillevin for the French Vasculitis Study Group⁷, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Intensive Care Unit, Cochin Hospital, Paris, France, ⁴Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁵CHU Louis Pradel, Lyon, Lyon, France, ⁶Internal Medicine, CHU, Clermont-Ferrand, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁸HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁹Department of Internal Medicine, Rennes University Hospital, Rennes, France, ¹⁰University of Lyon, LYON, France, ¹¹Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹²Internal Medicine, CH, Valenciennes, France, ¹³Internal Medicine, Hôpital de Niort, Niort, France, ¹⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France
Background/Purpose Rituximab (RTX) was shown to be as effective as cyclophosphamide to induce remission in patients with ANCA-associated vasculitis (AAV). The prospective MAINRITSAN trial compared…
Abstract Number: 1775 • 2014 ACR/ARHP Annual Meeting
Predicting Relapse in Patients with Granulomatosis with Polyangiitis – the Potential Use of Monitoring in Vitro ANCA Production
Judith Land¹, Wayel H. Abdulahad¹, Coen A. Stegeman², Peter Heeringa³ and Abraham Rutgers¹, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Nephrology, University Medical Center Groningen, Groningen, Netherlands, ³Pathology and Medical Biology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose Patients with granulomatosis with polyangiitis (GPA) suffer from frequent disease relapses, with up to 50% of patients relapsing within 5 years. Several risk factors…
Abstract Number: 1773 • 2014 ACR/ARHP Annual Meeting
Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO-ANCA Associated Vasculitis
Takahiro Nunokawa¹, Naoto Yokogawa², Kota Shimada¹ and Shoji Sugii², ¹Department of Rheumatic diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ²Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
Background/Purpose: Recently several case reports of serous otitis media (SOM), hypertrophic pachymeningitis (HP) and cranial neuropathy (CN) have been reported in connection with MPO-ANCA associated…
Abstract Number: 1766 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinicopathologically- and Serologically-Based Classification Systems for ANCA-Associated Vasculitis
Sebastian Unizony¹, Eli M. Miloslavsky¹, Miguel Villarreal², Peter A. Merkel³, Paul Monach⁴, E. William St. Claire⁵, Cees Kallenberg⁶, David Ikle², Robert F. Spiera⁷, Nadia Tchao⁸, Deborah J. Phippard⁸, Linna Ding⁹, Carol A. Langford¹⁰, Philip Seo¹¹, Gary S. Hoffman¹², John H. Stone¹ and Ulrich Specks¹³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Rho, Chapel Hill, NC, ³University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, Boston University, Boston, MA, ⁵Rheumatology, Duke University School of Medicine, Durham, NC, ⁶Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Immune Tolerance Network, Bethesda, MD, ⁹NIAID, Bethesda, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹²Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose Genome-wide association studies suggest that PR3-ANCA-positive ANCA-associated vasculitis (AAV) is genetically distinct from MPO-ANCA AAV. We evaluated patients enrolled in the RAVE trial according…
Abstract Number: 1765 • 2014 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3
Takamasa Murosaki, Takeo Sato, Yoichiro Akiyama, Katsuya Nagatani and Seiji Minota, Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan
Background/Purpose: To correlate the clinical characteristics of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with myeloperoxidase (MPO)-ANCA and proteinase-3 (PR3)-ANCA, and to detect clinical characteristics of…
Abstract Number: 1783 • 2014 ACR/ARHP Annual Meeting
The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival
Valeria Scaglioni¹, Marina Scolnik¹, Luis J. Catoggio¹, Carlos Federico Varela², Gustavo Greloni², Silvia Christiansen³ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Nephrology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Pathology Service. Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose : Histological changes in renal biopsy are the gold standard for establishing the diagnosis of antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis (GN). In 2010 a…
Abstract Number: 1755 • 2014 ACR/ARHP Annual Meeting
Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation
Melissa Parker, David Gold, Koustubh Ranade and Ethan Grant, Translational Sciences, MedImmune, LLC, Gaithersburg, MD
Background/Purpose ANCA vasculitis is characterized by the presence of autoantibodies directed against MPO, PR3 and other neutrophil proteins. Binding of these autoantibodies to activated neutrophils…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 1764 • 2014 ACR/ARHP Annual Meeting
Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis
Santhi Penmetsa¹, N. Suzanne Emil², Joshua Duchesne¹, Wilmer Sibbitt Jr.³, Arthur Bankhurst⁴ and Roderick Fields⁵, ¹Rheumatology, University of New Mexico Health sciences center, Albuquerque, NM, ²Rheumatology, Presbyterian Medical Group, Rio Rancho, NM, ³Rheumatology, University of New mexico health sciences center, Albuquerque, NM, ⁴Rheum/ MSC 105550, University of NM Med Ctr, Albuquerque, NM, ⁵Division of Rheumatology, University of New Mexico health Sciences center, Albuquerque, NM
Background/Purpose Objective: To compare various factors including clinical manifestations, laboratory data and mortality in between two groups of patients with anti-neutrophil cytoplasmic antibody (ANCA) positive…
Abstract Number: 804 • 2014 ACR/ARHP Annual Meeting
Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature
Alice Sy¹, Natasha Dehghan², Nader A. Khalidi³, Lillian Barra⁴, Simon Carette⁵, David Cuthbertson⁶, Gary S. Hoffman⁷, Curry L Koening⁸, Carol A. Langford⁹, Carol McAlear¹⁰, Paul A. Monach¹¹, Larry W. Moreland¹², Philip Seo¹³, Ulrich Specks¹⁴, Steven R. Ytterberg¹⁵, Gert Van Assche¹⁶, Peter A. Merkel¹⁰ and Christian Pagnoux⁵, ¹Medicine Division, London, ON, Canada, ²Rheumatology Division, Vancouver, BC, Canada, ³Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, ⁴Rheumatology, St. Joseph's Health Care, London, ON, Canada, ⁵Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Department of Biostatistics, University of South Florida, Tampa, FL, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ⁹Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Rheumatology, Boston University, Boston, MA, ¹²Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹³Johns Hopkins Vasculitis Center, Rheumatology Division, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic, Rochester, MN, ¹⁵Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁶Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Small case series suggested that vasculitis and inflammatory bowel disease (IBD; Crohn’s disease [CD] or ulcerative colitis [UC]) can co-occur more commonly than the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].